Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for pertuzumab-induced GI toxicities in HER2+ breast cancer
NCT04249622Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in gastrointestinal toxicity, sponsored by Mayo Clinic. Started Sep 2020; status: terminated.
02
Drugs
rifaximin
03
Conditions
gastrointestinal toxicity
Beyond the preview
Go deeper on NCT04249622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249622.